ArticlePharmaceutical research2003
Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
Article in Pharmaceutical research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 155 citations in OpenAlex.
- Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers.European journal of clinical pharmacology · 2008Trial
- Utility of a physiologically-based pharmacokinetic model for investigating time-dependent variability in the fetal-to-maternal plasma concentration ratio of digoxin.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Review
- Physiologically Based Pharmacokinetic Modeling of Digoxin in Adult and Pediatric Patients with Heart Failure.Pharmaceutics · 2026Article
- Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?Journal of pharmacokinetics and pharmacodynamics · 2025Article
- Applicability of MDR1 Overexpressing Abcb1KO-MDCKII Cell Lines for Investigating In Vitro Species Differences and Brain Penetration Prediction.Pharmaceutics · 2024Article
- Investigation of the Uptake and Transport of Two Novel Camptothecin Derivatives in Caco-2 Cell Monolayers.Molecules (Basel, Switzerland) · 2022Article
- Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models.Frontiers in pharmacology · 2022Article
- Knockout of ABC transporters by CRISPR/Cas9 contributes to reliable and accurate transporter substrate identification for drug discovery.Frontiers in pharmacology · 2022Article
- Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration andInternational journal of pharmaceutics: X · 2021Article
- Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.Journal of clinical pharmacology · 2021Article
- Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs.Pharmaceutics · 2021Article
- Development of a Hierarchical Support Vector Regression-Based In Silico Model for Caco-2 Permeability.Pharmaceutics · 2021Article
- From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation.Frontiers in chemistry · 2021Review
- Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.Pharmacology & therapeutics · 2020Review
- Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.Clinical pharmacokinetics · 2020Review
- Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition.CPT: pharmacometrics & systems pharmacology · 2019Article
- Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.The Journal of pharmacology and experimental therapeutics · 2017Article
- Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.European journal of drug metabolism and pharmacokinetics · 2016Article
- Simulation and Prediction of the Drug-Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling.CPT: pharmacometrics & systems pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this work was to determine whether P-glycoprotein (P-gp) modulates absorptive and secretory transport equally across polarized epithelium (i.e., Caco-2 cell monolayers) for structurally diverse P-gp substrates, a requirement for the use of the efflux ratio to quantify P-gp-mediated attenuation of absorption across intestinal epithelium.
methodsStudies were performed in Caco-2 cell monolayers. Apparent permeability (P(app)) in absorptive (P(app,AB)) and secretory (P(app,BA)) directions as well as efflux ratios (P(app,BA)/P(app,AB)) were determined for substrates as a function of concentration. Transport of these compounds (10 microM) was measured under normal conditions and in the presence of the P-gp inhibitor, GW918 (1 microM), to dissect the effect of P-gp on absorptive and secretory transport. Apparent biochemical constants of P-gp-mediated efflux activity were calculated for both transport directions.
resultsEfflux ratios for rhodamine 123 and digoxin were comparable (approx. 10). However, transport studies in the presence of GW918 revealed that P-gp attenuated absorptive transport of digoxin by approx. 8-fold but had no effect on absorptive transport of rhodamine 123 (presumably because absorptive transport of rhodamine 123 occurs via paracellular route). The apparent Km for P-gp-mediated efflux of digoxin was > 6-fold larger in absorptive vs. secretory direction. For structurally diverse P-gp substrates (acebutolol, colchicine, digoxin, etoposide, methylprednisolone, prednisolone, quinidine, and talinolol) apparent Km was approximately 3 to 8-fold greater in absorptive vs. secretory transport direction, whereas apparent J(max) was somewhat similar in both transport directions.
conclusionsP-gp-mediated efflux activity observed during absorptive and secretory transport was asymmetric for all substrates tested. For substrates that crossed polarized epithelium via transcellular pathway in both directions, this difference appears to be caused by greater apparent Km of P-gp-mediated efflux activity in absorptive vs. secretory direction. These results clearly suggest that use of efflux ratios could be misleading in predicting the extent to which P-gp attenuates the absorptive transport of substrates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.